Search research articles
Contact Us
Filters
Showing results (631-640 of 657) with videos related to
Page
of 66
Sort By:
Frontiers in Oncology
|
August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay
Thomas Powles, Amanda Young, Halla Nimeiri, et al.
Science Translational Medicine
|
March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux, Andreas Roller, Vesna Pulko, et al.
Nature Medicine
|
August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R Gandara, Sarah M Paul, Marcin Kowanetz, et al.
Nature Communications
|
August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis
Sreekanth P Reddy, Ramona Britto, Katyayni Vinnakota, et al.
Cancer Cell
|
November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J Motzer, Romain Banchereau, Habib Hamidi, et al.
The Journal of Antibiotics
|
January 27, 2009
Exploring the positional attachment of glycopeptide/beta-lactam heterodimers
Daniel D Long, James B Aggen, Jason Chinn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 5, 2020
A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
Richard S P Huang, James Haberberger, Eric Severson, et al.
Cancer Discovery
|
October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Meagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid Leukemia
Gege Gui, Laura W Dillon, Niveditha Ravindra, et al.
Page
of 66
Search research articles
Search
Showing results (631-640 of 657) with videos related to
Sort By:
Page
of 66
Frontiers in Oncology
|
August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay
Thomas Powles, Amanda Young, Halla Nimeiri, et al.
Science Translational Medicine
|
March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux, Andreas Roller, Vesna Pulko, et al.
Nature Medicine
|
August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R Gandara, Sarah M Paul, Marcin Kowanetz, et al.
Nature Communications
|
August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis
Sreekanth P Reddy, Ramona Britto, Katyayni Vinnakota, et al.
Cancer Cell
|
November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J Motzer, Romain Banchereau, Habib Hamidi, et al.
The Journal of Antibiotics
|
January 27, 2009
Exploring the positional attachment of glycopeptide/beta-lactam heterodimers
Daniel D Long, James B Aggen, Jason Chinn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 5, 2020
A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
Richard S P Huang, James Haberberger, Eric Severson, et al.
Cancer Discovery
|
October 31, 2020
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
Meagan Montesion, Karthikeyan Murugesan, Dexter X Jin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid Leukemia
Gege Gui, Laura W Dillon, Niveditha Ravindra, et al.
Page
of 66